First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population

Jakobsson, Maria; Nilsson, Fredrik; Strambi, Angela; Arpegård, Johannes; Dalén, Johan

doi:10.1080/14796694.2024.2401309

Future Oncology

2024

DOI: 10.1080/14796694.2024.2401309

|View full text |Cite

First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population

Maria Jakobsson,

Fredrik Nilsson,

Angela Strambi

et al.

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Jakobsson,

Strambi,

Nilsson

et al. 2024

Future Oncology

View full text Add to dashboard Cite

Aim: Assess the time-to-treatment discontinuation (TTD) and overall survival (OS) in a Swedish metastatic renal cell carcinoma (mRCC) nationwide cohort who received second-line axitinib. Methods: Retrospective analysis of 110 patients with mRCC treated with second-line axitinib in Sweden (2012–2019). Patients included in the study received axitinib after mainly first-line sunitinib or pazopanib. Results: The median (95% CI) TTD of patients who received second-line axitinib was 5.2 (3.7–6.1) months with 6 (5.5%) patients still receiving treatment at the time of analysis. Median (95% CI) OS was 12.2 (7.7–14.2) months. Conclusion: The results are consistent with previous findings in mRCC and add to the evidence demonstrating efficacy of second-line axitinib, after failure of a prior anti-angiogenic therapy in a real-world setting. Clinical Trial Registration: NCT04669366 ( ClinicalTrials.gov )

show abstract

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Jakobsson,

Strambi,

Nilsson

et al. 2024

Future Oncology

View full text Add to dashboard Cite

show abstract

scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.

Contact Info

customersupport@researchsolutions.com

10624 S. Eastern Ave., Ste. A-614

Henderson, NV 89052, USA

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Blog Terms and Conditions API Terms Privacy Policy Contact Cookie Preferences Do Not Sell or Share My Personal Information

Made with 💙 for researchers

Part of the Research Solutions Family.

First-line sunitinib treatment modification in patients with mRCC: nationwide analysis of the Swedish population

Cited by 1 publication

References 37 publications

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Real-world experience of second-line axitinib in metastatic renal cell carcinoma: analysis of the Swedish population

Contact Info

Product

Resources

About